This report analyzes the merger and acquisition (M&A) activity in Q1 2026 in the Pharma sector.
In Q1 2026, the global pharma sector recorded a drop in deal value to $55.4 billion, down 31.5% from Q4 2025. Deal volume edged up 0.9% to 108 M&A transactions. Oncology emerged as the leading therapeutic area recording 43 deals.
In Q1 2026, the global pharma sector recorded a drop in deal value to $55.4 billion, down 31.5% from Q4 2025. Deal volume edged up 0.9% to 108 M&A transactions. Oncology emerged as the leading therapeutic area recording 43 deals.
Report Scope
- This report provides an overview of M&A activity globally in Q1 2026 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q1 2026 in the Pharma sector.
Reasons to Buy
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Pharma M&A Analysis in Q1 2026
2.1 Pharma M&A Insights: Deal spotlight
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Trends in Pharma
5 Ownership Type: Private Vs Public (Volume)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A in Pharma by Deal Size Analysis
8 Top M&A Deals in Pharma Q1 2026
9 Regional M&A Comparison in Pharma - Q1 2026
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound M&A Deals in Pharma - Q1 2026
12 Regional M&A Trends in Pharma by Value and Volume
13 M&A Analysis in Pharma by Top 10 Countries
14 M&A Analysis in Pharma by Top 10 Therapy Areas
15 Further Information
15.1 Methodology
16 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Gilead Sciences
- Arcellx
- Eli Lilly
- Centessa Pharmaceuticals
- Terns Pharmaceuticals
- Merck
- Biogen
- Apellis Pharmaceuticals
- Novartis
- Pikavation Therapeutics
- Les Laboratoires Servier
- Day One Biopharmaceuticals
- Orna Therapeutics
- Ouro Medicines
- RAPT Therapeutics
- Excellergy
